Published on 05/12/2025

Missing Data & Imputation: Guardrails for Regulated Use

As Artificial Intelligence (AI) and Machine Learning (ML) technologies increasingly permeate the pharmaceutical landscape, ensuring their compliance with Good Automated Manufacturing Practice (GxP) guidelines becomes paramount. This article serves as a comprehensive guide for pharmaceutical professionals focusing on AI/ML model validation, particularly addressing the critical factors of intended use, data readiness, bias testing, model verification, and explainability. Leveraging these guidelines will help in aligning with regulatory authorities including the FDA, EMA, and MHRA.

Understanding AI/ML Model Validation

AI/ML model validation involves systematically ensuring that generated algorithms meet predefined business objectives while also adhering to regulatory standards. Effective validation assures stakeholders that AI/ML products generate reliable outcomes, especially in high-stakes environments such as pharmaceuticals.

The Essence of Intended Use

Starting with the concept of intended use, it is crucial for pharma professionals to define the purpose and scope of AI/ML models clearly. This aspect fundamentally guides the validation process. Each model should be tailored to specific regulatory frameworks, underlining its intended application.

• Define the Problem Statement: Clarify what specific issue the AI/ML model aims to address in the pharma context.
• Identify the Target Population: Understanding who or what will benefit from the use of the model is essential for validation.
• Specify Parameters: Document the performance metrics crucial for evaluating the model’s effectiveness, such as accuracy, sensitivity, and specificity.

Documenting Intended Use

Documentation surrounding the intended use must be rigorous. Maintaining records that outline the project scope, the reasoning behind the model design, and the stated objectives can not only guide development but also serve as vital evidence during audits.

Data Readiness and Curation

The concept of data readiness extends beyond mere availability; it encompasses the process of ensuring data are appropriately formatted, comprehensive, and representative of the target population. Poor data quality can lead to invalid results, rendering AI/ML applications unreliable.

Key Steps in Data Readiness Curation

• Data Collection: Gather data from diverse, relevant sources. This may encompass clinical trials, historical studies, or electronic health records.
• Data Cleaning: Eliminate inaccuracies, duplicates, and outliers to enhance dataset integrity.
• Data Transformation: Ensure data is structured appropriately for the AI/ML model, which may include normalization or categorical encoding.
• Data Validation: Before using data for model training, it is critical to assess the completeness and richness of data attributes.

Assessing Data Bias and Fairness

Bias can severely affect model performance and legitimacy. Embedding bias and fairness testing during the data readiness phase is essential to mitigate risks. Professionals should implement regular audits to examine how different subgroups may be represented in training datasets.

Model Verification and Validation

In pharmaceutical applications, the differentiation between model verification and validation is vital. While verification focuses on determining whether the model is built correctly, validation examines whether the right model is built for its intended purpose.

Model Verification Techniques

• Unit Testing: Implement testing at the individual component level to ensure that all parts function as expected.
• Integration Testing: Validate that combined components work together seamlessly, particularly when dealing with complex data sources.
• Performance Testing: Analyze the model’s computational efficiency and speed under various conditions.

Model Validation Approaches

• Cross-validation: Utilize cross-validation strategies such as k-fold to append robustness to your model’s generalizability.
• External Validation: Test the model against external datasets to assess its performance in real-world scenarios.
• Stakeholder Review: Seek feedback from industry experts to validate the model from a practical application perspective.

Explainability in AI/ML

As regulatory standards push for transparency in AI/ML use, explainability plays a crucial role. Explainable AI (XAI) allows stakeholders and regulators to comprehend how models arrive at their conclusions, fostering trust and acceptance.

Best Practices for Achieving Explainability

• Model Transparency: Choose models that inherently provide insight into their decision-making boundaries, such as decision trees or linear regression models.
• Post-hoc Interpretability: Employ techniques such as SHAP (SHapley Additive exPlanations) or LIME (Local Interpretable Model-agnostic Explanations) to elucidate model predictions.
• Comprehensive Reporting: Document and communicate how decisions are derived from data inputs, ensuring clarity for auditors and end-users.

Drift Monitoring and Re-validation

Once a model is implemented, it is crucial to have mechanisms in place for drift monitoring. Data and environmental changes can cause performance degradation, necessitating re-validation processes to maintain the model’s relevance and efficacy.

Key Elements of Drift Monitoring

• Performance Metrics Tracking: Regularly monitor the performance metrics defined during the intended use phase to identify deviation.
• Data Quality Audits: Conduct audits on incoming data for continual quality assurance, assessing for changes that could indicate drift.
• Trigger for Re-validation: Establish clear guidelines on when to initiate re-validation, such as after significant data updates or operational shifts.

Documentation and Audit Trails

In the realm of regulated use, maintaining an accurate and meticulous documentation trail is paramount to ensure compliance with standards such as 21 CFR Part 11 and Annex 11. Comprehensive records facilitate verification, validation, and the ability to retrace steps if required during audits.

Components of Robust Documentation

• Validation Plans: Outline expected outcomes, timelines, and personnel involved in the validation processes.
• Test Plans and Reports: Include detailed documentation of all verification and validation tests conducted, maintaining strict adherence to protocols.
• Audit Trails: Implement electronic systems that automatically log user actions and changes in model parameters or data handling to ensure traceability.

AI Governance and Security

Governance and security frameworks specifically tailored for AI in pharmaceutical applications can help institutions navigate the complexities associated with regulatory compliance. An effective governance plan covers areas such as regulatory alignment, risk management, and operational policies.

Implementing AI Governance Guidelines

• Establish a Governance Framework: Create a structured oversight committee that includes domain specialists to guide AI/ML initiatives through their lifecycle.
• Risk Management Processes: Identify potential risks associated with model failures or data breaches and outline mitigation strategies.
• Ongoing Training: Regularly train staff on both technology and compliance requirements to ensure adherence to evolving regulations.

Conclusion

In conclusion, the validation of AI/ML models within pharmaceutical applications is multifaceted and requires careful planning, rigorous testing, and thorough documentation. By understanding and implementing practices surrounding intended use, data readiness, bias assessment, model verification, and explainability, professionals can align their AI/ML initiatives with regulatory compliance and ensure quality outcomes. Furthermore, fostering a culture of continuous improvement through drift monitoring, governance, and security measures will help strengthen the integrity of AI/ML deployment in the life sciences sector.